Navigation Links
Bisexuality not a transitional phase among women, according to new research
Date:1/15/2008

WASHINGTON -- Bisexuality in women appears to be a distinctive sexual orientation and not an experimental or transitional stage that some women adopt "on their way" to lesbianism, according to new research published by the American Psychological Association.

The study of 79 non-heterosexual women over 10 years found that bisexual women maintained a stable pattern of attraction to both sexes. In addition, the research appears to have debunked the stereotype that bisexual women are uninterested in or unable to commit to long-term monogamous relationships.

"This research provides the first empirical examination of competing assumptions about the nature of bisexuality, both as a sexual identity label and as a pattern of nonexclusive sexual attraction and behavior," wrote University of Utah psychologist Lisa M. Diamond, PhD, who conducted the study. "The findings demonstrate considerable fluidity in bisexual, unlabeled and lesbian women's attractions, behaviors and identities and contribute to researchers' understanding of the complexity of sexual-minority development over the life span."

Results of the research were published in the January issue of Developmental Psychology, published by the APA. This special issue of the journal focuses on research into psychological topics concerning sexual orientation and gender identity.

Diamond used interview data collected five times over a decade from 79 women who identified as lesbian, bisexual or unlabeled. The subjects initially ranged in age from 18 to 25 years old.

Among Diamond's findings:

  • Bisexual and unlabeled women were more likely than lesbians to change their identity over the course of the study, but they tended to switch between bisexual and unlabeled rather than to settle on lesbian or heterosexual as their identities.

  • Seventeen percent of respondents switched from a bisexual or unlabeled identity to heterosexual during the study -- but more than half of these women switched back to bisexual or unlabeled by the end.

  • By year 10, most of the women were involved in long-term (i.e., more than a year in length) monogamous relationships -- 70 percent of the self-identified lesbians, 89 percent of the bisexuals, 85 percent of the unlabeled women and 67 percent of those who were then calling themselves heterosexual.

  • Women's definitions of lesbianism appeared to permit more flexibility in behavior than their definitions of heterosexuality. For example, of the women who identified as lesbian in the last round of interviews, 15 percent reported having sexual contact with a man during the prior two years. In contrast, none of the women who settled on a heterosexual label at that point reported having sexual contact with a woman within the previous two years.

"This provides further support for the notion that female sexuality is relatively fluid and that the distinction between lesbian and bisexual women is not a rigid one," Diamond wrote.


'/>"/>

Contact: Pam Willenz
pwillenz@apa.org
202-336-5707
American Psychological Association
Source:Eurekalert

Related medicine news :

1. Seabrook House Opens Transitional Living Facility: Seabrook West
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
4. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
5. Cytopia Commences Phase II Cancer Drug Study
6. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
7. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
8. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
9. Early Phase II results show bosutinib safe, effective for CML
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... A stressful ... at work can also decrease overall productivity and performance in the workplace. The goal ... , During the last few weeks of April, Clearview Resolution Services will be shutting ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology: